Cost-Effectiveness of a One-Time Universal Hepatitis B Screening in the United States

Join Hep B United and Dr. Mehlika Toy from the Asian Liver Center at Stanford University School of Medicine to discuss the cost-effectiveness of a one-time universal screening for chronic hepatitis B infection among adults in the United States.

In the U.S., an estimated 2.4 million people are living with chronic hepatitis B infection. Despite CDC and U.S. Preventive Services Task Force recommendations to screen adults at high risk for infection that have been in place for over a decade, a significant majority of people (~65-75%) remain undiagnosed. With current screening practice, 33% of people are diagnosed, 36% are linked to care and 18% of the diagnosed are receiving treatment. This webinar will provide a background on current screening practice, barriers and challenges and discuss results of a study to assess the economic and public health impact of a one-time universal screening of the general adult population for chronic hepatitis B infection in the U.S.